艾塞那肽对不同体质量指数2型糖尿病患者代谢指标的影响

发布时间：2018-06-14 19:24

本文选题：体质量指数 + 型糖尿病　；参考：《中国药房》2016年02期

【摘要】：目的:探讨艾塞那肽对不同体质量指数(BMI)2型糖尿病患者代谢指标的影响。方法:106例2型糖尿病患者按照不同BMI分为正常组(35例)、超重组(35例)和肥胖组(36例)。在原有降糖治疗基础上,给予3组患者艾塞那肽治疗。比较3组患者治疗前后的血压、体质量、BMI、各项血糖指标及甘油三酯水平,并观察其不良反应发生情况。结果:超重组与肥胖组患者治疗后的血压、体质量、BMI均显著优于治疗前,差异具有统计学意义(P0.05)。3组患者治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白、甘油三酯水平均显著低于治疗前,差异具有统计学意义(P0.05)。超重组与肥胖组患者的体质量和BMI变化幅度均显著大于正常组,差异具有统计学意义(P0.05)。3组患者均未出现严重并发症。结论:艾塞那肽适合于超重、肥胖2型糖尿病患者的治疗。
[Abstract]:Objective: to investigate the effect of Isenapeptide on metabolic indexes of BMI2 diabetic patients with different body mass index (BMI). Methods 106 patients with type 2 diabetes were divided into normal group (35 cases) and obesity group (36 cases) according to different BMI. On the basis of the original hypoglycemic therapy, three groups of patients were treated with Isenapeptide. The blood pressure, body mass, blood glucose index and triglyceride level were compared before and after treatment, and the adverse reactions were observed. Results: the blood pressure, body weight and BMI of the patients with hyperrecombination and obesity were significantly better than those before treatment. There were significant differences in fasting blood glucose, 2 h postprandial blood glucose and glycosylated hemoglobin between the two groups. The level of triglyceride was significantly lower than that before treatment, and the difference was statistically significant (P 0.05). The changes of body mass and BMI in hyperrecombination group and obesity group were significantly higher than those in normal group, and there was no serious complication in group P0.053.The difference was statistically significant. Conclusion: Isenapeptide is suitable for the treatment of overweight and obese type 2 diabetic patients.
【作者单位】：嵊州市人民医院内分泌科;
【分类号】：R587.1

【参考文献】